Compare Hyatt Hotels Corporation (H) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Hyatt Hotels Corporation trades at $176.67 (market cap $16.27B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Hyatt Hotels Corporation is far larger — about 207.1× Inovio Pharmaceuticals Inc's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| H | INO | |
|---|---|---|
Market Cap | $16.27B | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $2.87 |
52-Week Low | $135.42 | $0.66 |
Enterprise Value | $20.17B | $49.56M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $176.29, up 3.65% today, with a bearish technical outlook but strong recent earnings beats. The stock shows a high P/E of 213.14 and modest net margin of 1.1%, while cash flow trends are volatile. Analyst consensus is mixed with a $199.55 price target, and recent news highlights valuation concerns amid growth initiatives.
Outlook balances operational momentum from fee growth and RevPAR gains against rich valuation and debt risks. Investment opportunity lies in sustained travel demand, but risks include project delays, regional weakness, and high leverage. The stock requires patience for growth to justify premium multiples.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
